FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113257038> ?p ?o ?g. }

• W2113257038 endingPage "1373" @default.
• W2113257038 startingPage "1366" @default.
• W2113257038 abstract "Biologic therapies include:(1) naturally occurring or modified biologic compounds such as vaccines (live, live attenuated, or killed microorganisms), hormone extracts, and blood products;(2) recombinant proteins or peptides—for example, granulocyte macrophage colony stimulating factor and growth hormone;(3) monoclonal antibodies and fusion proteins; and (4) antisense oligonucleotides to nucleic acids. These biologic therapies, which are targeted towards specific disease mechanisms, have the potential to provide more effective and safe treatments for human diseases. Clinical trials have demonstrated that inhibition of the cytokine tumour necrosis factor α(TNF) and inhibition of the selective adhesion molecules α4 integrin and α4β7 integrin are effective in the treatment of various forms of the inflammatory bowel diseases (IBD) ulcerative colitis (UC) and Crohn’s disease (CD). It is also clear that drug toxicity related to biologic therapy, including hypersensitivity, serum sickness, autoimmunity, infection, and immunogenicity may occur. This article reviews the progress made to date in the treatment of IBD with biologic therapies, concentrating primarily on the TNF inhibitors infliximab, etanercept, adalimumab, CDP870, CDP571, and onercept, and on the selective adhesion molecule inhibitors natalizumab and MLN-02, but also reviewing other potentially promising therapies targeted towards other mechanisms of action (table 1).View this table: Table 1  Biotechnology compounds that have been or are being evaluated for the treatment of patients with inflammatory bowel disease### Comparative mechanisms of action for various anti-TNF agentsTNF is elevated in the mucosa of patients with CD,1 and inhibition of TNF has been an effective treatment strategy.2 Comparison of various anti-TNF agents with respect to biologic construction, ability to bind soluble and membrane bound TNF, ability to fix complement, ability to mediate antibody dependent cytotoxicity, ability to cause T cell apoptosis, and efficacy in unselected patients versus efficacy primarily in patients with elevated concentrations of C reactive protein (CRP) is shown in table 2. The efficacy of the anti-TNF agent infliximab in unselected patients with …" @default.
• W2113257038 created "2016-06-24" @default.
• W2113257038 creator A5083726032 @default.
• W2113257038 date "2004-09-01" @default.
• W2113257038 modified "2023-09-26" @default.
• W2113257038 title "Biologics in inflammatory bowel disease: how much progress have we made?" @default.
• W2113257038 cites W1534544965 @default.
• W2113257038 cites W186275704 @default.
• W2113257038 cites W1976546496 @default.
• W2113257038 cites W1997999969 @default.
• W2113257038 cites W2000500639 @default.
• W2113257038 cites W2001681806 @default.
• W2113257038 cites W2002883352 @default.
• W2113257038 cites W2005275461 @default.
• W2113257038 cites W2008629972 @default.
• W2113257038 cites W2017443151 @default.
• W2113257038 cites W2022253360 @default.
• W2113257038 cites W2022290270 @default.
• W2113257038 cites W2022507641 @default.
• W2113257038 cites W2024162533 @default.
• W2113257038 cites W2026116536 @default.
• W2113257038 cites W2035291009 @default.
• W2113257038 cites W2036242475 @default.
• W2113257038 cites W2038535814 @default.
• W2113257038 cites W2056852317 @default.
• W2113257038 cites W2062109784 @default.
• W2113257038 cites W2071644653 @default.
• W2113257038 cites W2074740380 @default.
• W2113257038 cites W2081341089 @default.
• W2113257038 cites W2081833623 @default.
• W2113257038 cites W2086721113 @default.
• W2113257038 cites W2090198994 @default.
• W2113257038 cites W2090685459 @default.
• W2113257038 cites W2093894520 @default.
• W2113257038 cites W2099599782 @default.
• W2113257038 cites W2102980544 @default.
• W2113257038 cites W2112768046 @default.
• W2113257038 cites W2113591882 @default.
• W2113257038 cites W2114990062 @default.
• W2113257038 cites W2118178438 @default.
• W2113257038 cites W2118232932 @default.
• W2113257038 cites W2118688515 @default.
• W2113257038 cites W2118877038 @default.
• W2113257038 cites W2119825375 @default.
• W2113257038 cites W2127281820 @default.
• W2113257038 cites W2127693350 @default.
• W2113257038 cites W2128890061 @default.
• W2113257038 cites W2131652664 @default.
• W2113257038 cites W2138223843 @default.
• W2113257038 cites W2141139109 @default.
• W2113257038 cites W2151354830 @default.
• W2113257038 cites W2152803022 @default.
• W2113257038 cites W2157202822 @default.
• W2113257038 cites W2164861161 @default.
• W2113257038 cites W2166393142 @default.
• W2113257038 cites W2167844752 @default.
• W2113257038 cites W2171341132 @default.
• W2113257038 cites W2172135053 @default.
• W2113257038 cites W2318415918 @default.
• W2113257038 cites W2321453230 @default.
• W2113257038 cites W2326330820 @default.
• W2113257038 cites W2344230491 @default.
• W2113257038 cites W4249622436 @default.
• W2113257038 doi "https://doi.org/10.1136/gut.2003.025452" @default.
• W2113257038 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1774209" @default.
• W2113257038 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15306602" @default.
• W2113257038 hasPublicationYear "2004" @default.
• W2113257038 type Work @default.
• W2113257038 sameAs 2113257038 @default.
• W2113257038 citedByCount "56" @default.
• W2113257038 countsByYear W21132570382012 @default.
• W2113257038 countsByYear W21132570382013 @default.
• W2113257038 countsByYear W21132570382014 @default.
• W2113257038 countsByYear W21132570382015 @default.
• W2113257038 countsByYear W21132570382016 @default.
• W2113257038 countsByYear W21132570382019 @default.
• W2113257038 countsByYear W21132570382022 @default.
• W2113257038 crossrefType "journal-article" @default.
• W2113257038 hasAuthorship W2113257038A5083726032 @default.
• W2113257038 hasBestOaLocation W21132570381 @default.
• W2113257038 hasConcept C126322002 @default.
• W2113257038 hasConcept C2777572184 @default.
• W2113257038 hasConcept C2778260677 @default.
• W2113257038 hasConcept C2779134260 @default.
• W2113257038 hasConcept C71924100 @default.
• W2113257038 hasConceptScore W2113257038C126322002 @default.
• W2113257038 hasConceptScore W2113257038C2777572184 @default.
• W2113257038 hasConceptScore W2113257038C2778260677 @default.
• W2113257038 hasConceptScore W2113257038C2779134260 @default.
• W2113257038 hasConceptScore W2113257038C71924100 @default.
• W2113257038 hasIssue "9" @default.
• W2113257038 hasLocation W21132570381 @default.
• W2113257038 hasLocation W21132570382 @default.
• W2113257038 hasLocation W21132570383 @default.
• W2113257038 hasLocation W21132570384 @default.
• W2113257038 hasLocation W21132570385 @default.
• W2113257038 hasOpenAccess W2113257038 @default.
• W2113257038 hasPrimaryLocation W21132570381 @default.

• next